Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Q3 Pharma Earnings Preview: Novo Nordisk, Shire And Teva

Executive Summary

Pricing pressure and difficulties with market access in competitive classes will be common themes as Teva, Novo Nordisk and Shire report third quarter sales and earnings.

You may also be interested in...



Plenty Of Potential For Roche's Entrectinib Despite Lack Of ESMO Enthusiasm

Roche's up and down ESMO is best summed up by the response to data presented on its personalised cancer med entrectinib – good but perhaps not as good as others.

Positive Phase III For Darolutamide In Prostate Cancer Could Improve Options For Orion

Top-line results from the Phase III ARAMIS study indicate the next-generation oral androgen receptor antagonist, darolutamide, has met its primary endpoint and could provide a boost for Finland's multinational and now pure-play pharma company, Orion, plus Bayer too.

More Good News For Bayer's Larotrectinib Ahead Of FDA Verdict

An update on Bayer and Loxo's tissue-agnostic therapy for cancers with NTRK gene fusions has impressed, confirming the sustained durable effect of larotrectinib as it nears its action date for approval in the US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel